Cancer News and Research

Latest Cancer News and Research

$Long-term androgen deprivation therapy increases risk of fracture in older men with prostate cancer$

Long-term androgen deprivation therapy increases risk of fracture in older men with prostate cancer

Men with history of fracture and comorbidities are at an increased risk of fracture after long-term use of androgen deprivation therapy, and initiating this therapy should be carefully considered in older men with localized prostate cancer.

9 Nov 2010

EntreMed to present data of ENMD-2076 Phase 1 study in multiple myeloma and leukemia at ASH 2010

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today announced presentations for its Phase 2 oncology drug candidate, ENMD-2076. Data for the ENMD-2076 Phase 1 studies in multiple myeloma and leukemia will be presented by EntreMed investigators at the 2010 Annual Meeting of the American Society of Hematology (ASH) to be held December 4-7 at the Orange County Convention Center in Orlando, Florida.

9 Nov 2010

ARIAD reports $20.4 million net loss for third quarter 2010

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2010 and provided an update on corporate developments.

9 Nov 2010

ArQule reduces third quarter net loss to $6,394,000

ArQule, Inc. today reported its results of operations for the fiscal quarter and nine months ended September 30, 2010.

9 Nov 2010

Semafore's SF1126 for B-cell chronic lymphocytic leukemia granted FDA orphan drug designation

Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).

9 Nov 2010

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has held its second meeting with the Australian Therapeutic Goods Administration ("TGA") to discuss milestones for approval of PV-10 for treatment of metastatic melanoma. The TGA is the part of the Australian Government's Department of Health and Ageing responsible for the assessment, approval and monitoring of therapeutic goods available in Australia. The initial meeting with the TGA was held in October 2008.

9 Nov 2010

Human blood from adult human skin

In an important breakthrough, scientists at McMaster University have discovered how to make human blood from adult human skin.

9 Nov 2010

Study finds lack of medication adherence among people with RA and lupus

People with rheumatic diseases don't take their medication on a regular basis, and this leads to poor outcomes in their disease treatment, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

Study says looking older does not necessarily point to poor health

Even though most adults want to avoid looking older than their actual age, research led by St. Michael's Hospital shows that looking older does not necessarily point to poor health. The study found that a person needed to look at least 10 years older than their actual age before assumptions about their health could be made.

9 Nov 2010

Patients with germinal center-like structures face greater risk of developing non-Hodgkin's lymphoma

Biopsying the glands that produce saliva to test for germinal center-like formation when someone is diagnosed with primary Sjögren's Syndrome can predict later development of non-Hodgkin's lymphoma, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

Study finds cancer cells subject to several major chromosomal changes at the same time

New progress has been made on the road to understanding the origins of genetic changes in tumour cells. The prevalent theory has been that genetic changes in tumour cells come about in multiple stages over a long time. However, a recent study by researchers at Lund University shows that this does not have to be the case at all, but that the cancer cells instead can be subject to several major chromosomal changes at the same time.

9 Nov 2010

Spectral Molecular Imaging awarded $190,172 QTDP grant for development of melanoma detection system

Cascade Technologies Corp., announced today that its wholly-owned subsidiary Spectral Molecular Imaging, Inc. (SMI) has received a grant under the Qualifying Therapeutic Discovery Project (QTDP) program to advance the development of the company's SkinSpect system for the detection of melanoma and other skin cancers.

9 Nov 2010

Research report on current and evolving technologies in drug delivery

The drug delivery market is a rapidly evolving force in the pharmaceutical industry. Within this segment injectables have a significant role to play at present with the increasing use of proteins and peptides.

9 Nov 2010

GTx third quarter net loss decreases to $8.6 million

GTx, Inc. today reported financial results for the third quarter of 2010. The net loss for the quarter ended September 30, 2010 was $8.6 million compared with a net loss of $12.8 million for the quarter ended September 30, 2009. For the nine months ended September 30, 2010, GTx reported net income of $22.8 million compared with a net loss of $35.4 million for the same period in 2009.

9 Nov 2010

Priaxon and Technical University Munich partner to develop anti-infective agents against infectious diseases

Priaxon AG, Munich, and the University Hospital Rechts der Isar (Technical University Munich) announce their cooperation for the development of new, highly selective anti-infective agents against a novel protein target class of widely spread infectious diseases. Their joint project is supported in the framework of the top cluster support project of the German Federal Ministry of Education and Research, coordinated by BioM GmbH.

9 Nov 2010

Research may help develop new therapies for aggressive prostate cancer

A monoclonal antibody targeting a well known cell surface protein inhibited prostate cancer growth and metastasis in an aggressive form of the disease that did not respond to hormone therapy, according to a study by researchers with the UCLA Department of Urology and UCLA's Jonsson Comprehensive Cancer Center.

9 Nov 2010

Patented cover for stethoscopes will curb hospital-acquired infections

Saints Medical Center is pleased to announce that Richard H. Ma, M.D, chair of its hospitalist department, has received a patent for a lightweight plastic cover for stethoscopes that will dramatically reduce hospital-acquired infections.

9 Nov 2010

Innovative method for in-cell gene manipulation

A cross-disciplinary Small Medicine and Advanced Research Translation (SMART) team led by Prof. Dar-Bin Shieh of Institute of Oral Medicine in Medical College at National Cheng Kung University (NCKU), Tainan, Taiwan, has announced a breakthrough in the precision in-cell gene scission at pre-designed sequence sites using Artificial Targeting Light Activated Nano Scissors (ATLANS) and a custom build photonic device.

9 Nov 2010

Johns Hopkins scientists identify protein mechanism that regulates cell division

By tracking the flow of information in a cell preparing to split, Johns Hopkins scientists have identified a protein mechanism that coordinates and regulates the dynamics of shape change necessary for division of a single cell into two daughter cells.

9 Nov 2010

EUSA completes BLA filing for ERWINASE in treatment of acute lymphoblastic leukemia

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ERWINASE(R) (L-asparaginase derived from Erwinia chrysanthemi) for use in the treatment of acute lymphoblastic leukemia in patients with hypersensitivity to E. coli-derived asparaginase.

9 Nov 2010

Cancer News and Research

Latest Cancer News and Research

Long-term androgen deprivation therapy increases risk of fracture in older men with prostate cancer

EntreMed to present data of ENMD-2076 Phase 1 study in multiple myeloma and leukemia at ASH 2010

ARIAD reports $20.4 million net loss for third quarter 2010

ArQule reduces third quarter net loss to $6,394,000

Semafore's SF1126 for B-cell chronic lymphocytic leukemia granted FDA orphan drug designation

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

Human blood from adult human skin

Study finds lack of medication adherence among people with RA and lupus

Study says looking older does not necessarily point to poor health

Patients with germinal center-like structures face greater risk of developing non-Hodgkin's lymphoma

Study finds cancer cells subject to several major chromosomal changes at the same time

Spectral Molecular Imaging awarded $190,172 QTDP grant for development of melanoma detection system

Research report on current and evolving technologies in drug delivery

GTx third quarter net loss decreases to $8.6 million

Priaxon and Technical University Munich partner to develop anti-infective agents against infectious diseases

Research may help develop new therapies for aggressive prostate cancer

Patented cover for stethoscopes will curb hospital-acquired infections

Innovative method for in-cell gene manipulation

Johns Hopkins scientists identify protein mechanism that regulates cell division

EUSA completes BLA filing for ERWINASE in treatment of acute lymphoblastic leukemia

Understanding the DNA Damage Response in Innate Immunity eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in